Floatz logo

Pelacarsen

Lipoproteinemia

University Medical Centre LjubljanaN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lipoproteinemia cohort.

Asset / SponsorPhaseRating
ADVICOR COMPONENT NIACIN
Ludwig-Maximilians - University of Munich
Phase 4BB
LAROPIPRANT
Ludwig-Maximilians - University of Munich
Phase 4B
Alirocumab
University Medical Centre Ljubljana
N/AD
Evolocumab
University Medical Centre Ljubljana
N/AD

Same molecule, other indications

Pelacarsen is also rated in:

cardiovascular disorderDormant
B
Indicative ·
59 / 100
View asset →
acute coronary syndromeDormant
D
Indicative ·
30 / 100
View asset →
inflammatory diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →